EmpaDuo Tablets 5/500 mg
Empagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Myung Moon Pharmaceutical Co., Ltd.
MFDS item code 202201375 · Approved 2022.04.04
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to improve blood glucose control in adult patients with type 2 diabetes when combined with diet and exercise. It is particularly prescribed with Empagliflozin and Metformin in cases where blood glucose is not adequately controlled. It is also administered to patients with type 2 diabetes who have cardiovascular disease, but caution regarding the risk of cardiovascular events must be considered. Thus, this medication is effective for blood sugar management in diabetes patients and can be safely taken under the guidance of appropriate healthcare providers.
The recommended dose is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional blood glucose control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their current doses of empagliflozin and metformin. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take a double dose at one time; if this happens, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Contraindications, item 2)). Elderly Patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.
This medication can cause rare but serious side effects such as severe lactic acidosis, so it should not be administered to patients at high risk of lactic acidosis. Severe hypoglycemia may occur when used with other glucose-lowering agents, so careful observation for hypoglycemic symptoms is required. It should not be used in patients with moderate or severe renal impairment or those at risk of acute kidney injury. In cases of acute conditions such as acute infections, heart failure, pre- and post-surgery, or dehydration, administration of this medication should be temporarily stopped and can be resumed once the patient's condition is stabilized. It is safest not to use this medication in pregnant women or women who may become pregnant, as well as in breastfeeding women. This medication affects kidney function; therefore, regular kidney function tests should be conducted before and during administration, and if kidney function declines, the use of this medication should be discontinued. During the course of treatment, care should be taken for dehydration, hypotension, electrolyte imbalances, and particularly older patients or those with cardiovascular disease should be monitored more closely. The risk of urinary tract and genital infections may increase, so any infection symptoms should be reported to healthcare providers immediately. Vitamin B12 deficiency may occur; thus, periodic checks of vitamin B12 levels during long-term use are recommended. Alcohol consumption may increase the risk of lactic acidosis; therefore, excessive drinking should be avoided while taking this medication. This medication increases fluid excretion, which may cause fluid loss, requiring caution in patients at risk for dehydration or substantial fluid loss. Since there is a risk of hypoglycemia, immediate action should be taken if hypoglycemic symptoms occur, and dosage adjustments may be needed, especially when used with other glucose-lowering agents. Additionally, this medication should be discontinued before and after specific imaging procedures involving contrast agents and can be resumed once kidney function returns to normal after testing. Elderly patients may be at risk for decreased kidney function, so dosage adjustments and regular kidney function monitoring are necessary. During treatment, patients should not suspend or change doses arbitrarily without consulting a physician, and any unusual symptoms should be reported to healthcare providers immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air and moisture from entering. It is advisable to maintain storage temperature between 1 and 30 degrees Celsius at room temperature. This ensures prolonged effectiveness and safe usage.
Orange-yellow, biconvex, oval film-coated tablet
10 tablets/box [10 tablets/PTPX1], 60 tablets/box [10 tablets/PTPX6], 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Myung Moon Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.